Mezagitamab
Based on 1 publication(s) in Google Scholar
Mezagitamab (TAK-079) is a IgG1λ anti-CD38 monoclonal antibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.76%
- CAS No.: 2227490-52-8
- Masse moléculaire:143.7 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Mezagitamab
More
Activité biologique
Human IgG1 lambda
Human
CD38
Mezagitamab binds to CD38, allosterically inhibits the enzymatic activity of CD38, induces apoptosis by antibody-dependent cellular cytotoxicity (ADCC, activates immune cells such as NK cells) and complement-dependent cytotoxicity (CDC, activates the complement system)[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mezagitamab (3 mg/kg, iv,once weekly for 8 weeks) prevents collagen-induced arthritis in cynomolgus monkey models[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Cynomolgus monkey models[4]
-
Dosage:0.03-100 mg/kg
-
Administration:iv, once or twice a week for 4-13 weeks
-
Result:Reduced numbers of NK/B/T cells.
-
Animal Model:Collagen-induced arthritis in cynomolgus monkey models[4]
-
Dosage:3 mg/kg
-
Administration:iv,once weekly for 8 weeks
-
Result:Inhibited the progression of arthritis.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 lambda
ELISA, FACS, Functional assay
-
Immobilized CD38 Protein, Human can bind Mezagitamab. The EC50 for this effect is 61.97 ng/mL. -
Flow Cytometry analysis of Raji cells labelling CD38 (red) with Mezagitamab (anti-CD38) (HY-P99730). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 lambda1 (HY-P99992). Black-Unlabelled control, cells without incubation with primary antibody.
Chemical Information
-
CAS No. 2227490-52-8
-
Appearance Liquid
-
Masse moléculaire 143.7 kDa
-
Color Colorless to light yellow
-
SMILES
[Mezagitamab]
-
Synonyms
TAK-079
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
Pureté et documentation
-
Fiche technique (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[2]. Jadoon Y, et al. Immunotherapy in multiple myeloma. Cancer Treat Res Commun. 2021;29:100468. [Content Brief]
[3]. Kuter DJ. Novel therapies for immune thrombocytopenia. Br J Haematol. 2022 Mar;196(6):1311-1328. [Content Brief]
[4]. Roepcke S, et al., Pharmacokinetics and pharmacodynamics of the cytolytic anti-CD38 human monoclonal antibody TAK-079 in monkey - model assisted preparation for the first in human trial. Pharmacol Res Perspect. 2018 Jun;6(3):e00402. [Content Brief]
[5]. Korver W, et al., A Reduction in B, T, and Natural Killer Cells Expressing CD38 by TAK-079 Inhibits the Induction and Progression of Collagen-Induced Arthritis in Cynomolgus Monkeys. J Pharmacol Exp Ther. 2019 Aug;370(2):182-196. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Mezagitamab Related Classifications
HY-P99730 Related Classifications
Powered by Bioz